omalizumab
Showing 1 - 25 of 106
Chronic Spontaneous Urticaria Trial (Remibrutinib, Placebo to remibrutinib, Placebo to omalizumab)
Not yet recruiting
- Chronic Spontaneous Urticaria
- Remibrutinib
- +3 more
- (no location specified)
Sep 20, 2023
Asthma in Children, Atopy, Viral Upper Respiratory Infection Trial in Washington (Omalizumab, Placebo)
Recruiting
- Asthma in Children
- +2 more
- Omalizumab
- Placebo
-
Washington, District of ColumbiaChildren's National Hospital
Aug 26, 2022
Food Allergy Trial in Odense C (Omalizumab, Placebo)
Recruiting
- Food Allergy
- Omalizumab
- Placebo
-
Odense C, Funen, DenmarkOdense Research Center for Anaphylaxis, Allergy Center, Odense U
Sep 20, 2022
Omalizumab in Children With Allergic Asthma.
Completed
- Allergic Asthma
- Omalizumab
-
East Hanover, New JerseyNovartis Investigative Site
Jun 29, 2022
Nasal Polyps Trial in Shiraz (Omalizumab, SNOT22 score)
Not yet recruiting
- Nasal Polyps
- Omalizumab
- SNOT22 score
-
Shiraz, Fars, Iran, Islamic Republic ofImam Reza Allergy and Immunology clinic, Shiraz University of Me
May 31, 2022
XOLAIR Outcomes in Pediatric Allergic Asthma United States
Completed
- Asthma
- Omalizumab
-
East Hanover, New JerseyNovartis Investigational Site
Dec 15, 2021
Asthma Trial in Shanghai (Omalizumab)
Completed
- Asthma
- Omalizumab
-
Shanghai, Shanghai, ChinaShanghai Xuhui Central Hospital
Oct 8, 2021
Chronic Urticaria, Idiopathic Trial in Aurora (Omalizumab)
Recruiting
- Chronic Urticaria, Idiopathic
- Omalizumab
-
Aurora, ColoradoUniversity of Colorado Anschutz
Mar 23, 2022
Peanut Allergy, Food Allergy Trial in United States (Omalizumab, )
Active, not recruiting
- Peanut Allergy
- Food Allergy
- Omalizumab
- placebo
-
Stanford, California
- +3 more
Jan 11, 2022
Moderate-to-severe Allergic Asthma Trial in United States (Omalizumab)
Terminated
- Moderate-to-severe Allergic Asthma
- Omalizumab
-
Rolling Hills Estates, California
- +11 more
Feb 16, 2022
Asthma Trial in Hangzhou (JYB1904, Omalizumab, JYB1904 Placebo)
Active, not recruiting
- Asthma
- JYB1904
- +2 more
-
Hangzhou, Zhejiang, ChinaShulan (Hangzhou) Hospital
Oct 23, 2022
Idiopathic Angioedema Trial in Madison (Omalizumab, Placebos)
Completed
- Idiopathic Angioedema
- Omalizumab
- Placebos
-
Madison, WisconsinUW Madison
Oct 21, 2021
Atopic Healthy Subjects, Adult Subjects With Mild Allergic Diseases Trial in Korea, Republic of (YH35324, Placebo, Omalizumab)
Completed
- Atopic Healthy Subjects
- Adult Subjects With Mild Allergic Diseases
- YH35324
- +2 more
-
Suwon-si, Gyeonggi-do, Korea, Republic of
- +3 more
Jan 26, 2023
Seasonal Allergic Rhinitis Trial in Beijing (Omalizumab)
Completed
- Seasonal Allergic Rhinitis
- Omalizumab
-
Beijing, Beijing, ChinaBeijing Tongren Hospital
Jan 26, 2021
Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria Trial in Seongnam-si, Suwon-si, Seoul (YH35324,
Recruiting
- Allergic Disease
- +3 more
- YH35324
- +2 more
-
Seongnam-si, Gyeonggi-do, Korea, Republic of
- +4 more
Jul 24, 2023
Allergic Bronchopulmonary Aspergillosis Trial (Prednisone tablet, itraconazole, Omalizumab)
Not yet recruiting
- Allergic Bronchopulmonary Aspergillosis
- Prednisone tablet
- +2 more
- (no location specified)
Nov 19, 2021
Chronic Urticaria Trial in Denver (Omalizumab)
Completed
- Chronic Urticaria
- Omalizumab
-
Denver, ColoradoUniversity of Colorado Hospital
Nov 10, 2020
Asthma, Allergic Rhinitis, Atopic Dermatitis Trial in Sacramento (Omalizumab, Placebo)
Completed
- Asthma
- +2 more
- Omalizumab
- Placebo
-
Sacramento, CaliforniaUC Davis Department of Dermatology
Jun 21, 2021
Chronic Rhinosinusitis With Nasal Polyps, Asthma Trial in Worldwide (Dupilumab, Omalizumab, Placebo)
Recruiting
- Chronic Rhinosinusitis With Nasal Polyps
- Asthma
- Dupilumab
- +2 more
-
Tucson, Arizona
- +65 more
Jul 12, 2022
Symptomatic Dermographism Trial in Freiburg, Mainz (Omalizumab, Placebo)
Completed
- Symptomatic Dermographism
- Omalizumab
- Placebo
-
Freiburg, Germany
- +1 more
Oct 9, 2020
Atopic Healthy Subjects, Adult Subjects With Mild Allergic Diseases Trial in Seongnam-si, Suwon-si, Seoul (YH35324, Placebo,
Recruiting
- Atopic Healthy Subjects
- Adult Subjects With Mild Allergic Diseases
- YH35324
- +2 more
-
Seongnam-si, Gyeonggi-do, Korea, Republic of
- +3 more
Nov 11, 2022
Urticaria Chronic Trial in Baltimore (Omalizumab)
Completed
- Urticaria Chronic
- Omalizumab
-
Baltimore, MarylandJohns Hopkins Asthma and Allergy Center
May 20, 2021
Asthma, Eosinophilic Asthma Trial in New Lambton (Mepolizumab, Omalizumab)
Unknown status
- Asthma
- Eosinophilic Asthma
- Mepolizumab
- Omalizumab
-
New Lambton, New South Wales, AustraliaJohn Hunter Hospital
Oct 6, 2020
Aspirin Sensitivity Trial in Cleveland (Omalizumab, )
Completed
- Aspirin Sensitivity
- Omalizumab
- placebo
-
Cleveland, OhioThe Cleveland Clinic
Oct 12, 2020